Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors

References

• Platanias LC. Biological responses to arsenic compounds. J Biol Chem 2009; 284:18583 - 7; http://dx.doi.org/10.1074/jbc.R900003200; PMID: 19363033
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116:3751 - 7; http://dx.doi.org/10.1182/blood-2010-02-269621; PMID: 20705755
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218 - 20; http://dx.doi.org/10.1126/science.275.5297.218; PMID: 8985016
   PubMed Web of Science ®Google Scholar
• Dörrie J, Gerauer H, Wachter Y, Zunino SJ. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 2001; 61:4731 - 9; PMID: 11406544
   PubMed Web of Science ®Google Scholar
• Sommers RK, Brady WA, Moore WH Jr.. Dichotic ear preferences of stuttering children and adults. Percept Mot Skills 1975; 41:931 - 8; http://dx.doi.org/10.2466/pms.1975.41.3.931; PMID: 1215135
   PubMed Web of Science ®Google Scholar
• Su JL, Lin MT, Hong CC, Chang CC, Shiah SG, Wu CW, Chen ST, Chau YP, Kuo ML. Resveratrol induces FasL-related apoptosis through Cdc42 activation of ASK1/JNK-dependent signaling pathway in human leukemia HL-60 cells. Carcinogenesis 2005; 26:1 - 10; http://dx.doi.org/10.1093/carcin/bgh220; PMID: 15217905
   PubMed Web of Science ®Google Scholar
• Puissant A, Grosso S, Jacquel A, Belhacene N, Colosetti P, Cassuto JP, Auberger P. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J 2008; 22:1894 - 904; http://dx.doi.org/10.1096/fj.07-101394; PMID: 18245170
   PubMed Web of Science ®Google Scholar
• Fulda S. Regulation of cell death and survival by resveratrol: implications for cancer therapy. Anticancer Agents Med Chem 2012; 12:874 - 9; http://dx.doi.org/10.2174/187152012802650129; PMID: 22292764
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004; 23:6702 - 11; http://dx.doi.org/10.1038/sj.onc.1207630; PMID: 15273734
   PubMed Web of Science ®Google Scholar
• Duraj J, Bodo J, Sulikova M, Rauko P, Sedlak J. Diverse resveratrol sensitization to apoptosis induced by anticancer drugs in sensitive and resistant leukemia cells. Neoplasma 2006; 53:384 - 92; PMID: 17013532
   PubMed Web of Science ®Google Scholar
• Taranto D, Suozzo R, de Sio I, Romano M, Caporaso N, Del Vecchio Blanco C, Coltorti M. Effect of metoclopramide on transmural oesophageal variceal pressure and portal blood flow in cirrhotic patients. Digestion 1990; 47:56 - 60; http://dx.doi.org/10.1159/000200477; PMID: 2292350
   PubMed Web of Science ®Google Scholar
• Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S, Auberger P. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 2010; 70:1042 - 52; http://dx.doi.org/10.1158/0008-5472.CAN-09-3537; PMID: 20103647
   PubMed Web of Science ®Google Scholar
• Fang Y, DeMarco VG, Nicholl MB. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Sci 2012; 103:1090 - 8; http://dx.doi.org/10.1111/j.1349-7006.2012.02272.x; PMID: 22417066
   PubMed Web of Science ®Google Scholar
• Fang Y, Bradley MJ, Cook KM, Herrick EJ, Nicholl MB. A potential role for resveratrol as a radiation sensitizer for melanoma treatment. J Surg Res 2013; 183:645 - 53; http://dx.doi.org/10.1016/j.jss.2013.02.037; PMID: 23522452
   PubMed Web of Science ®Google Scholar
• Liao HF, Kuo CD, Yang YC, Lin CP, Tai HC, Chen YY, Chen YJ. Resveratrol enhances radiosensitivity of human non-small cell lung cancer NCI-H838 cells accompanied by inhibition of nuclear factor-kappa B activation. J Radiat Res 2005; 46:387 - 93; http://dx.doi.org/10.1269/jrr.46.387; PMID: 16394628
   PubMed Web of Science ®Google Scholar
• Goussetis DJ, Altman JK, Glaser H, McNeer JL, Tallman MS, Platanias LC. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem 2010; 285:29989 - 97; http://dx.doi.org/10.1074/jbc.M109.090530; PMID: 20656687
   PubMed Web of Science ®Google Scholar
• Goussetis DJ, Gounaris E, Wu EJ, Vakana E, Sharma B, Bogyo M, Altman JK, Platanias LC. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood 2012; 120:3555 - 62; http://dx.doi.org/10.1182/blood-2012-01-402578; PMID: 22898604
   PubMed Web of Science ®Google Scholar
• Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, Platanias LC. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 2002; 277:44988 - 95; http://dx.doi.org/10.1074/jbc.M207176200; PMID: 12239215
   PubMed Web of Science ®Google Scholar
• Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, Nebreda AR, Davis RJ, Platanias LC. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 2006; 66:6763 - 71; http://dx.doi.org/10.1158/0008-5472.CAN-05-3699; PMID: 16818652
   PubMed Web of Science ®Google Scholar
• McNeer JL, Goussetis DJ, Sassano A, Dolniak B, Kroczynska B, Glaser H, Altman JK, Platanias LC. Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1. Mol Pharmacol 2010; 77:828 - 35; http://dx.doi.org/10.1124/mol.109.061507; PMID: 20159944
   PubMed Web of Science ®Google Scholar
• Kannan-Thulasiraman P, Katsoulidis E, Tallman MS, Arthur JS, Platanias LC. Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide. J Biol Chem 2006; 281:22446 - 52; http://dx.doi.org/10.1074/jbc.M603111200; PMID: 16762916
   PubMed Web of Science ®Google Scholar
• Dolniak B, Katsoulidis E, Carayol N, Altman JK, Redig AJ, Tallman MS, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Platanias LC. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem 2008; 283:12034 - 42; http://dx.doi.org/10.1074/jbc.M708816200; PMID: 18299328
   PubMed Web of Science ®Google Scholar
• Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore L, Riccioni R, Costanzo A, et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 2008; 112:2450 - 62; http://dx.doi.org/10.1182/blood-2007-10-114348; PMID: 18583568
   PubMed Web of Science ®Google Scholar
• Galvin JP, Altman JK, Szilard A, Goussetis DJ, Vakana E, Sassano A, Platanias LC. Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses. Cancer Biol Ther 2013; 14:411 - 6; http://dx.doi.org/10.4161/cbt.23760; PMID: 23377826
   PubMed Web of Science ®Google Scholar
• Altman JK, Yoon P, Katsoulidis E, Kroczynska B, Sassano A, Redig AJ, Glaser H, Jordan A, Tallman MS, Hay N, et al. Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem 2008; 283:1992 - 2001; http://dx.doi.org/10.1074/jbc.M705227200; PMID: 18048359
   PubMed Web of Science ®Google Scholar
• Yoon P, Giafis N, Smith J, Mears H, Katsoulidis E, Sassano A, Altman J, Redig AJ, Tallman MS, Platanias LC. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 2006; 5:2815 - 23; http://dx.doi.org/10.1158/1535-7163.MCT-06-0263; PMID: 17121928
   PubMed Web of Science ®Google Scholar
• Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453:1072 - 8; http://dx.doi.org/10.1038/nature07016; PMID: 18469801
   PubMed Web of Science ®Google Scholar
• Yu M, Xue J, Li Y, Zhang W, Ma D, Liu L, Zhang Z. Resveratrol protects against arsenic trioxide-induced nephrotoxicity by facilitating arsenic metabolism and decreasing oxidative stress. Arch Toxicol 2013; 87:1025 - 35; http://dx.doi.org/10.1007/s00204-013-1026-4; PMID: 23471352
   PubMed Web of Science ®Google Scholar
• Zhang W, Xue J, Ge M, Yu M, Liu L, Zhang Z. Resveratrol attenuates hepatotoxicity of rats exposed to arsenic trioxide. Food Chem Toxicol 2013; 51:87 - 92; http://dx.doi.org/10.1016/j.fct.2012.09.023; PMID: 23023136
   PubMed Web of Science ®Google Scholar
• Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009; 16:966 - 75; http://dx.doi.org/10.1038/cdd.2009.33; PMID: 19325568
   PubMed Web of Science ®Google Scholar
• Uddin S, Majchrzak B, Woodson J, Arunkumar P, Alsayed Y, Pine R, Young PR, Fish EN, Platanias LC. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem 1999; 274:30127 - 31; http://dx.doi.org/10.1074/jbc.274.42.30127; PMID: 10514501
   PubMed Web of Science ®Google Scholar
• Uddin S, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, Malik AB, Fish EN, Platanias LC. Protein kinase C-δ (PKC-δ ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002; 277:14408 - 16; http://dx.doi.org/10.1074/jbc.M109671200; PMID: 11839738
   PubMed Web of Science ®Google Scholar
• Vakana E, Altman JK, Glaser H, Donato NJ, Platanias LC. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood 2011; 118:6399 - 402; http://dx.doi.org/10.1182/blood-2011-01-332783; PMID: 22021366
   PubMed Web of Science ®Google Scholar
• Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 2010; 107:12469 - 74; http://dx.doi.org/10.1073/pnas.1005114107; PMID: 20616057
   PubMed Web of Science ®Google Scholar
• Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, Russo S, Barr S, Platanias LC. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011; 17:4378 - 88; http://dx.doi.org/10.1158/1078-0432.CCR-10-2285; PMID: 21415215
   PubMed Web of Science ®Google Scholar